Stock Track | Eikon Therapeutics Plummets 7.5% Intraday as Stock Debuts Below IPO Price

Stock Track

02/06

Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.

The decline came as the stock began trading on the Nasdaq Global Select Market, opening at $17.05 per share, significantly below its initial public offering price of $18. The company had upsized its IPO to 21.8 million shares, pricing at the top of its expected $16-$18 range, but investor demand appeared weaker than anticipated at the opening bell.

Founded in 2019 by Nobel laureates, Eikon Therapeutics is developing experimental cancer therapies, with its most advanced drug candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer. Interim analysis data from this study is expected in the second half of 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1180668695"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180668695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180668695?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 02:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180668695","market":"us","top_or_hot":-1,"title":"Stock Track | Eikon Therapeutics Plummets 7.5% Intraday as Stock Debuts Below IPO Price","media":"Stock Track","content":"<p>Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.</p><p>The decline came as the stock began trading on the Nasdaq Global Select Market, opening at $17.05 per share, significantly below its initial public offering price of $18. The company had upsized its IPO to 21.8 million shares, pricing at the top of its expected $16-$18 range, but investor demand appeared weaker than anticipated at the opening bell.</p><p>Founded in 2019 by Nobel laureates, Eikon Therapeutics is developing experimental cancer therapies, with its most advanced drug candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer. Interim analysis data from this study is expected in the second half of 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eikon Therapeutics Plummets 7.5% Intraday as Stock Debuts Below IPO Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eikon Therapeutics Plummets 7.5% Intraday as Stock Debuts Below IPO Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 02:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.</p><p>The decline came as the stock began trading on the Nasdaq Global Select Market, opening at $17.05 per share, significantly below its initial public offering price of $18. The company had upsized its IPO to 21.8 million shares, pricing at the top of its expected $16-$18 range, but investor demand appeared weaker than anticipated at the opening bell.</p><p>Founded in 2019 by Nobel laureates, Eikon Therapeutics is developing experimental cancer therapies, with its most advanced drug candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer. Interim analysis data from this study is expected in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EIKN","symbol_name":"Eikon Therapeutics","start_time":0,"source_url":"","article_id":"1180668695","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180668695","pubTimestamp":1770314678,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.The decline came as the stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EIKN":"Eikon Therapeutics"},"translate_title":"个股追踪|Eikon Therapeutics盘中暴跌7.5%股价低于IPO发行价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EIKN":1},"content_text":"Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.The decline came as the stock began trading on the Nasdaq Global Select Market, opening at $17.05 per share, significantly below its initial public offering price of $18. The company had upsized its IPO to 21.8 million shares, pricing at the top of its expected $16-$18 range, but investor demand appeared weaker than anticipated at the opening bell.Founded in 2019 by Nobel laureates, Eikon Therapeutics is developing experimental cancer therapies, with its most advanced drug candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer. Interim analysis data from this study is expected in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}